The global nucleic acid extraction and purification market was valued at USD 5.48 billion in 2025. The market is estimated at USD 5.86 billion in 2026 and is projected to reach USD 11.42 billion by 2036, at a CAGR of 6.9% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering demand drivers, extraction chemistries and automation, consumable pull-through, regulation and standards, cost per sample, the competitive landscape, and future growth opportunities.
The market, also known as the DNA and RNA extraction or nucleic acid isolation market, covers the laboratory kits, reagents, instruments, and consumables that recover clean DNA and RNA from clinical, research, and environmental samples. Column, bead, and solution-based kits for each major nucleic acid type are in scope, together with cleanup and size-selection reagents, automated systems from benchtop units to high-throughput workcells, and cartridges, plates, tips, and magnetic particles. Process-scale purification for biopharmaceutical manufacturing, sample collection and stabilization devices, library preparation kits other than cleanup reagents, and point-of-care systems that do not sell extraction separately are excluded.
Because every sample must be extracted before analysis, demand tracks total molecular testing volume, and the yield, purity, and integrity of the extracted material decide whether downstream PCR or sequencing succeeds. Illumina, Inc. reported second-quarter 2026 sequencing consumables revenue of USD 775 million, up 5%, and instrument revenue of USD 125 million, up 31%. In the same quarter, QIAGEN N.V. reported USD 182 million in sales from its Sample technologies business, up 9% at constant exchange rates, with automated consumables growing at a high-teens rate, while Tempus AI, Inc. reported a 31% rise in oncology testing volume.
The post-pandemic fall in infection testing left excess capacity and inventory in some markets, and low-cost Asian manufacturers and tender pressure have intensified price competition for standard kits. Automated systems require capital, service contracts, and platform-specific consumables, so many small laboratories and laboratories in lower-income countries continue to extract manually. Quality from FFPE, plasma, forensic, and environmental samples remains variable, and direct-to-PCR methods and point-of-care systems with built-in sample preparation reduce the need for separate extraction in some high-volume uses.
Cell-free DNA preparation for liquid biopsy, early cancer detection, prenatal testing, and transplant monitoring is a significant opportunity. Single-cell, spatial, and long-read sample preparation is another, as shown by QIAGEN's reported late-2025 deal to acquire Parse Biosciences for up to USD 280 million. Compact automation for hospital and regional laboratories, such as QIAGEN's QIAmini system planned for the second half of 2026, and extraction from non-invasive and applied-market samples also offer growth. Key trends include the move from silica columns to magnetic bead automation, the linking of extraction with PCR and library preparation through partnerships such as QIAGEN's with Hamilton and Inpeco, and coordinated multi-omics extraction for biobanks.
By product, the nucleic acid extraction and purification market is segmented into kits and reagents, instruments, and consumables and accessories. Kits & reagents are expected to hold the largest share in 2026, as a kit is used for every sample, kit ranges span nearly every sample type, and installed automated systems consume platform-specific kits on a recurring basis. Instruments are expected to grow at the highest CAGR, driven by automation in clinical and high-throughput laboratories, upgrades to next-generation platforms such as QIAsymphony Connect, and compact systems built for smaller sites. Consumables such as tips, plates, and magnetic particles grow with automated use.
By method, the nucleic acid extraction and purification market is segmented into silica column-based, magnetic bead-based, solution-based, and other extraction methods. Silica column-based methods are expected to account for the largest share in 2026, owing to the wide research use of spin columns, their simplicity and low capital cost, and their place in many validated protocols. Magnetic bead-based methods are expected to grow at the highest CAGR, as they suit automation, scale from single tubes to high-throughput plates, power most automated clinical and research systems, and perform well in cell-free DNA extraction and library cleanup. Other methods include filter, cellulose, and microfluidic formats.
By nucleic acid type, the nucleic acid extraction and purification market is segmented into genomic DNA, plasmid DNA, cell-free DNA, total RNA and mRNA, microRNA and small RNA, and viral and microbial nucleic acids. Genomic DNA is expected to account for the largest share in 2026, as it is isolated for sequencing, genotyping, genetic testing, biobanking, forensics, and research from very large numbers of blood, saliva, and tissue samples. Cell-free DNA is expected to grow at the highest CAGR, supported by liquid biopsy for cancer genotyping, residual disease monitoring, and early detection, wider use of noninvasive prenatal testing, and the need for dedicated methods to recover low-concentration DNA from plasma. Viral and microbial extraction stays tied to infection testing.
By sample type, the nucleic acid extraction and purification market is segmented into blood and plasma, tissue and FFPE samples, swabs and respiratory samples, cells and cell cultures, saliva, urine & stool, and plant, food & environmental samples. Blood & plasma are expected to account for the largest share in 2026, given the use of blood in genetic testing, biobanking, and research, plasma in liquid biopsy and viral load testing, and the high number of blood samples handled by clinical laboratories. Saliva, urine & stool are expected to grow at the highest CAGR, as non-invasive samples gain ground in genetic and infectious disease testing, colorectal cancer screening, and microbiome studies, and as home and remote collection becomes more common. Damaged FFPE tissue keeps demand high for premium kits.
By application, the nucleic acid extraction and purification market is segmented into life science research and NGS, infectious disease diagnostics, oncology and liquid biopsy, genetic and reproductive testing, forensics and human identification, and agriculture, food, veterinary & environmental testing. Life science research & NGS is expected to account for the largest share in 2026, reflecting the many laboratories that extract DNA and RNA for sequencing, PCR, gene expression, and cloning, growth in genomics, single-cell, and multi-omics research, and large population genomics and biobank programs. Oncology & liquid biopsy is expected to grow at the highest CAGR, driven by comprehensive genomic profiling, liquid biopsy, and residual disease testing and by the specialized extraction these tests need from FFPE tissue and plasma.
By end user, the nucleic acid extraction and purification market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, and other end users. Academic & research institutes are expected to account for the largest share in 2026, given the number of research laboratories using extraction kits, public funding for genomics and biomedical research, and the genome centers and biobanks run by research institutions. Hospitals & diagnostic laboratories are expected to grow at the highest CAGR, as molecular diagnostics, oncology testing, and liquid biopsy expand, clinical and reference laboratories automate extraction, and more hospitals bring molecular testing in house. Other end users include forensic and applied testing laboratories.
North America is expected to remain the largest regional nucleic acid extraction and purification market in 2026, supported by high volumes of molecular diagnostic, oncology, and sequencing tests, strong NIH and private research budgets, a large drug development industry, and home-grown suppliers including Thermo Fisher Scientific, Agilent Technologies, Danaher, Promega, Revvity, New England Biolabs, and Zymo Research. Europe holds a significant share, backed by leading research institutions, national genomics programs and biobanks, growing oncology and molecular testing, and companies such as QIAGEN, Roche, Merck KGaA, and MACHEREY-NAGEL.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, as sequencing and molecular testing expand quickly in China, India, Japan, and South Korea, governments and institutions invest in genomics, clinical laboratory networks grow, and domestic kit and instrument makers, particularly in China, scale up alongside established suppliers such as Japan's Takara Bio. Latin America and the Middle East & Africa remain smaller markets, with molecular diagnostics and research in Brazil and Mexico, Gulf genome programs, and infectious disease testing in Africa supporting demand.
The nucleic acid extraction and purification market is moderately consolidated, as large life science and diagnostics firms lead through big installed bases and broad kit ranges, while specialists and regional makers, mostly in Asia-Pacific, compete in standard products. Leading companies are launching next-generation automated platforms, building compact systems, widening kit ranges for liquid biopsy, tissue, and advanced sequencing, connecting extraction with downstream steps, and making acquisitions. Recent examples include QIAGEN's 2026 rollout of QIAsymphony Connect, first orders for QIAsprint Connect, the planned QIAmini launch, and its purchase of Parse Biosciences.
Key companies profiled in the report include QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Promega Corporation (U.S.), Revvity, Inc. (U.S.), Danaher Corporation (Beckman Coulter Life Sciences) (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Takara Bio Inc. (Japan), MACHEREY-NAGEL GmbH & Co. KG (Germany), Zymo Research Corporation (U.S.), and New England Biolabs, Inc. (U.S.).
The market, also known as the DNA and RNA extraction or nucleic acid isolation market, covers the laboratory kits, reagents, instruments, and consumables that recover clean DNA and RNA from clinical, research, and environmental samples. Column, bead, and solution-based kits for each major nucleic acid type are in scope, together with cleanup and size-selection reagents, automated systems from benchtop units to high-throughput workcells, and cartridges, plates, tips, and magnetic particles. Process-scale purification for biopharmaceutical manufacturing, sample collection and stabilization devices, library preparation kits other than cleanup reagents, and point-of-care systems that do not sell extraction separately are excluded.
Because every sample must be extracted before analysis, demand tracks total molecular testing volume, and the yield, purity, and integrity of the extracted material decide whether downstream PCR or sequencing succeeds. Illumina, Inc. reported second-quarter 2026 sequencing consumables revenue of USD 775 million, up 5%, and instrument revenue of USD 125 million, up 31%. In the same quarter, QIAGEN N.V. reported USD 182 million in sales from its Sample technologies business, up 9% at constant exchange rates, with automated consumables growing at a high-teens rate, while Tempus AI, Inc. reported a 31% rise in oncology testing volume.
Market Dynamics
Sequencing and molecular testing are the main drivers of the nucleic acid extraction and purification market, as every genome, transcriptome, single-cell, or long-read study starts with DNA or RNA isolation, and newer methods need high-molecular-weight DNA, intact RNA, and efficient cleanup and size selection. Oncology genomic profiling and liquid biopsy are a second driver, since small FFPE biopsies and plasma with very little fragmented cell-free DNA require specialized chemistries. Molecular infection testing has stayed well above pre-pandemic levels, surveillance of pathogens such as H5N1 relies on extraction, and the large fleet of automated systems installed during COVID-19 keeps using kits and cartridges. Automation adds demand as laboratories seek higher throughput, fewer errors, and relief from staff shortages.The post-pandemic fall in infection testing left excess capacity and inventory in some markets, and low-cost Asian manufacturers and tender pressure have intensified price competition for standard kits. Automated systems require capital, service contracts, and platform-specific consumables, so many small laboratories and laboratories in lower-income countries continue to extract manually. Quality from FFPE, plasma, forensic, and environmental samples remains variable, and direct-to-PCR methods and point-of-care systems with built-in sample preparation reduce the need for separate extraction in some high-volume uses.
Cell-free DNA preparation for liquid biopsy, early cancer detection, prenatal testing, and transplant monitoring is a significant opportunity. Single-cell, spatial, and long-read sample preparation is another, as shown by QIAGEN's reported late-2025 deal to acquire Parse Biosciences for up to USD 280 million. Compact automation for hospital and regional laboratories, such as QIAGEN's QIAmini system planned for the second half of 2026, and extraction from non-invasive and applied-market samples also offer growth. Key trends include the move from silica columns to magnetic bead automation, the linking of extraction with PCR and library preparation through partnerships such as QIAGEN's with Hamilton and Inpeco, and coordinated multi-omics extraction for biobanks.
Segment Analysis
The report analyzes the market by product, method, nucleic acid type, sample type, application, end user, and geography, helping stakeholders identify the most attractive growth areas.By product, the nucleic acid extraction and purification market is segmented into kits and reagents, instruments, and consumables and accessories. Kits & reagents are expected to hold the largest share in 2026, as a kit is used for every sample, kit ranges span nearly every sample type, and installed automated systems consume platform-specific kits on a recurring basis. Instruments are expected to grow at the highest CAGR, driven by automation in clinical and high-throughput laboratories, upgrades to next-generation platforms such as QIAsymphony Connect, and compact systems built for smaller sites. Consumables such as tips, plates, and magnetic particles grow with automated use.
By method, the nucleic acid extraction and purification market is segmented into silica column-based, magnetic bead-based, solution-based, and other extraction methods. Silica column-based methods are expected to account for the largest share in 2026, owing to the wide research use of spin columns, their simplicity and low capital cost, and their place in many validated protocols. Magnetic bead-based methods are expected to grow at the highest CAGR, as they suit automation, scale from single tubes to high-throughput plates, power most automated clinical and research systems, and perform well in cell-free DNA extraction and library cleanup. Other methods include filter, cellulose, and microfluidic formats.
By nucleic acid type, the nucleic acid extraction and purification market is segmented into genomic DNA, plasmid DNA, cell-free DNA, total RNA and mRNA, microRNA and small RNA, and viral and microbial nucleic acids. Genomic DNA is expected to account for the largest share in 2026, as it is isolated for sequencing, genotyping, genetic testing, biobanking, forensics, and research from very large numbers of blood, saliva, and tissue samples. Cell-free DNA is expected to grow at the highest CAGR, supported by liquid biopsy for cancer genotyping, residual disease monitoring, and early detection, wider use of noninvasive prenatal testing, and the need for dedicated methods to recover low-concentration DNA from plasma. Viral and microbial extraction stays tied to infection testing.
By sample type, the nucleic acid extraction and purification market is segmented into blood and plasma, tissue and FFPE samples, swabs and respiratory samples, cells and cell cultures, saliva, urine & stool, and plant, food & environmental samples. Blood & plasma are expected to account for the largest share in 2026, given the use of blood in genetic testing, biobanking, and research, plasma in liquid biopsy and viral load testing, and the high number of blood samples handled by clinical laboratories. Saliva, urine & stool are expected to grow at the highest CAGR, as non-invasive samples gain ground in genetic and infectious disease testing, colorectal cancer screening, and microbiome studies, and as home and remote collection becomes more common. Damaged FFPE tissue keeps demand high for premium kits.
By application, the nucleic acid extraction and purification market is segmented into life science research and NGS, infectious disease diagnostics, oncology and liquid biopsy, genetic and reproductive testing, forensics and human identification, and agriculture, food, veterinary & environmental testing. Life science research & NGS is expected to account for the largest share in 2026, reflecting the many laboratories that extract DNA and RNA for sequencing, PCR, gene expression, and cloning, growth in genomics, single-cell, and multi-omics research, and large population genomics and biobank programs. Oncology & liquid biopsy is expected to grow at the highest CAGR, driven by comprehensive genomic profiling, liquid biopsy, and residual disease testing and by the specialized extraction these tests need from FFPE tissue and plasma.
By end user, the nucleic acid extraction and purification market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, and other end users. Academic & research institutes are expected to account for the largest share in 2026, given the number of research laboratories using extraction kits, public funding for genomics and biomedical research, and the genome centers and biobanks run by research institutions. Hospitals & diagnostic laboratories are expected to grow at the highest CAGR, as molecular diagnostics, oncology testing, and liquid biopsy expand, clinical and reference laboratories automate extraction, and more hospitals bring molecular testing in house. Other end users include forensic and applied testing laboratories.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 19 countries and four rest-of-region groups. The regional analysis considers molecular diagnostic and sequencing volumes, research funding, clinical laboratory capacity, and the presence of extraction kit and instrument manufacturers.North America is expected to remain the largest regional nucleic acid extraction and purification market in 2026, supported by high volumes of molecular diagnostic, oncology, and sequencing tests, strong NIH and private research budgets, a large drug development industry, and home-grown suppliers including Thermo Fisher Scientific, Agilent Technologies, Danaher, Promega, Revvity, New England Biolabs, and Zymo Research. Europe holds a significant share, backed by leading research institutions, national genomics programs and biobanks, growing oncology and molecular testing, and companies such as QIAGEN, Roche, Merck KGaA, and MACHEREY-NAGEL.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, as sequencing and molecular testing expand quickly in China, India, Japan, and South Korea, governments and institutions invest in genomics, clinical laboratory networks grow, and domestic kit and instrument makers, particularly in China, scale up alongside established suppliers such as Japan's Takara Bio. Latin America and the Middle East & Africa remain smaller markets, with molecular diagnostics and research in Brazil and Mexico, Gulf genome programs, and infectious disease testing in Africa supporting demand.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard (market leaders, market differentiators, vanguards, and emerging players), and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial overviews, nucleic acid extraction and product portfolios, strategic developments, and SWOT analyses.The nucleic acid extraction and purification market is moderately consolidated, as large life science and diagnostics firms lead through big installed bases and broad kit ranges, while specialists and regional makers, mostly in Asia-Pacific, compete in standard products. Leading companies are launching next-generation automated platforms, building compact systems, widening kit ranges for liquid biopsy, tissue, and advanced sequencing, connecting extraction with downstream steps, and making acquisitions. Recent examples include QIAGEN's 2026 rollout of QIAsymphony Connect, first orders for QIAsprint Connect, the planned QIAmini launch, and its purchase of Parse Biosciences.
Key companies profiled in the report include QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Promega Corporation (U.S.), Revvity, Inc. (U.S.), Danaher Corporation (Beckman Coulter Life Sciences) (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Takara Bio Inc. (Japan), MACHEREY-NAGEL GmbH & Co. KG (Germany), Zymo Research Corporation (U.S.), and New England Biolabs, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global nucleic acid extraction and purification market.
- Explains how sequencing, oncology and liquid biopsy testing, infectious disease testing, and automation are shaping demand.
- Assesses the effect of post-pandemic normalization, price competition, automation costs, and extraction-free methods on suppliers.
- Identifies high-growth opportunities across product, method, nucleic acid type, sample type, application, end user, and region.
- Tracks magnetic bead automation, plasma and tissue chemistries, compact systems, and integrated workflows.
- Benchmarks leading suppliers on installed base, kit range, automation, and performance with difficult samples.
- Supports product planning, platform strategy, pricing, acquisition, and market entry decisions for kit and instrument makers, distributors, and investors.
Key Questions Answered
- How big is the global nucleic acid extraction and purification market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How do manual and automated extraction compare on throughput, cost, and quality?
- How does the installed base of automated systems drive recurring kit and consumable demand?
- Which products, methods, nucleic acid types, sample types, applications, and end users will grow the fastest?
- How are liquid biopsy, tissue profiling, and advanced sequencing changing extraction requirements?
- How do FDA rules, the EU IVDR, and preanalytical ISO standards affect clinical extraction products?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and what strategies are they pursuing?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Nucleic Acid Extraction and Purification Market, by Product
6. Nucleic Acid Extraction and Purification Market, by Method
7. Nucleic Acid Extraction and Purification Market, by Nucleic Acid Type
8. Nucleic Acid Extraction and Purification Market, by Sample Type
9. Nucleic Acid Extraction and Purification Market, by Application
10. Nucleic Acid Extraction and Purification Market, by End User
11. Nucleic Acid Extraction and Purification Market, by Geography
12. Competitive Landscape
13. Company Profiles
14. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd
- Promega Corporation
- Revvity, Inc.
- Danaher Corporation
- Agilent Technologies, Inc.
- Merck KGaA
- Takara Bio Inc.
- MACHEREY-NAGEL GmbH & Co. KG
- Zymo Research Corporation
- New England Biolabs, Inc.
